TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 60-85 years of age~* Female~* At least two years since last menstrual cycle~Exclusion Criteria:~* Abnormal or unexplained vaginal bleeding.~* Bone disorders, other than osteoporosis or low bone mass~* History of breast cancer, cancer of the uterus, or any cancer in the last five years (except skin cancer).~* History of cerebral vascular accidents or venous thromboembolic events~* Medications outlined

- Gender: FEMALE
- Minimum Age: 60 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~Completed the full study treatment period of 52 weeks in preceding phase III studies, and have been receiving secukinumab treatment during the maintenance phase of the preceding phase III studies, and show at least a partial response (PASI 50 or better) at Week 52 of the preceding phase III studies.~Written informed consent form.~Key Exclusion Criteria:~A protocol deviation in either of the preceding phase III studies which according to the investigator prevented the meaningful analysis of the extension study for the individual subject.~Ongoing use of prohibited psoriasis or non-psoriasis treatments.~Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (\>10 mIU/mL).~Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unwilling to use effective contraception during the study and for 16 weeks after stopping treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PASI 75 Responders (Type: PLACEBO_COMPARATOR): PASI 75 responders participated in randomized withdrawal. Subjects who were PASI 75 responders at Week 52 visit of the core studies (e.g.CAIN457A2302 or CAIN457A2303) and have been on secukinumab s.c. 150 mg or 300 mg in core studies were randomized to continue same s.c. doses of secukinumab in PFS or receive placebo every 4 weeks up to Week 152 or until relapse. Participants on first full relapse received loading dose followed by routine dosing with secukinumab s.c. 150 mg or 300 mg regimen.
- Partial responders (Type: EXPERIMENTAL): Partial responders were not randomized. Subjects who were partial responders at Week 52 visit in core studies (e.g.CAIN457A2302 or CAIN457A2303) and have been on secukinumab s.c. 150 mg or 300 mg in core studies did not participate in the randomized withdrawal. These subjects continued same treatment s.c. dose in PFS (secukinumab s.c. 150 mg or 300 mg) as they were receiving at the time of completing the maintenance period (Week 52) in the core studies.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RCT(Randomized Clinical Trial ) of Antibiotic Therapy in Chronic Endometritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. CD138 immunohistochemical staining of endometrial specimen showed presence of one or more plasma cells per 10HPF which confirmed chronic endometritis, according to published criteria.~2. women who were pre-menopausal.~3. no evidence of endometrial hyperplasia or malignancy or structural uterine pathology.~4. agreement to have a second endometrial biopsy \~4 weeks after the initial endometrial biopsy.~5. written informed consent obtained~Exclusion Criteria:~1. women who received steroid hormone therapy within one month of recruitment.~2. allergy or suspected allergy to the chosen antibiotic therapy.~3. women who developed any concurrent infection and received any antibiotic therapy during the period of study other than the one prescribed according to the study protocol.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Antibiotic group (Type: EXPERIMENTAL): This group received antibiotic therapy
- Control group (Type: NO_INTERVENTION): This group did not receive antibiotic therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Negative clinical history for varicella, herpes zoster, measles, mumps, and rubella~Exclusion Criteria:~* Received any measles, mumps, rubella, or varicella vaccine at any time prior to the study, or is anticipated to receive any of these vaccines outside the study~* Any congenital or acquired immune deficiency, neoplastic disease, or depressed immunity~* Received systemic immunomodulatory steroids within 3 months prior to entering the study or is expected to receive them during the course of the study~* History of allergy or anaphylactic reaction to neomycin, gelatin, sorbitol, egg proteins, chicken proteins, or any component of VARIVAX™ or M-M-R II™~* Received salicylates within 14 days prior to study vaccination~* Exposed to varicella, herpes zoster, measles, mumps, or rubella in the 4 weeks prior to study vaccination~* Received immune globulin, a blood transfusion, or blood-derived products within 5 months prior to study vaccination~* History of seizure disorder, including febrile seizure~* Fever illness (\>=102.2 °F \[39.0 °C\] within 72 hours prior to study vaccination~* History of thrombocytopenia~* Born to a human immunodeficiency virus (HIV)-infected mother~* Participated in any other clinical trial (other than a surveillance study) within 30 days prior to study enrollment.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 23 Months
- Healthy Volunteers: t

Study Arms:
- VARIVAX™ NSP + M-M-R II™ (Type: EXPERIMENTAL): VARIVAX™ New Seed Process 0.5 mL administered in the left arm and M-M-R II™ vaccine 0.5 mL administered in the right arm by subcutaneous injection on Day 1 and Day 91
- VARIVAX™ 2007 Process + M-M-R II™ (Type: ACTIVE_COMPARATOR): VARIVAX™ 2007 Process 0.5 mL administered in the left arm and M-M-R II™ vaccine 0.5 mL administered in the right arm by subcutaneous injection on Day 1 and Day 91

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence Study Between a 4-mg Dose of Fine Granules of Perampanel and a 4-mg Tablet of Perampanel in Healthy Japanese Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~Participants must meet all of the following criteria to be included in this study:~* Non-smoking, male or female age ≥20 years and ≤45 years old at the time of obtaining written informed consent. To be considered non-smokers, participants must have discontinued smoking from Screening before first dosing.~* Body Mass Index ≥18.5 and \<25.0 kilograms per meters squared at Screening~Exclusion Criteria~Participants who meet any of the following criteria will be excluded from this study:~* Females who are breastfeeding or pregnant at Screening or Baseline~* Clinically significant illness that requires medical treatment within 8 weeks or a clinically significant infection that requires medical treatment within 4 weeks before first dosing~* Evidence of disease that may influence the outcome of the study within 4 weeks before first dosing~* Any history of gastrointestinal surgery that may affect pharmacokinetic profiles of perampanel at Screening~* Any clinically abnormal symptom or organ impairment found by medical history at Screening, and physical examinations, vital signs, electrocardiogram (ECG) finding, or laboratory test results that require medical treatment at Screening~* A prolonged QT/QT corrected interval (QT interval, Fridericia correction \>450 milliseconds) as demonstrated by a repeated ECG at Screening or Baseline

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Treatment A (Type: EXPERIMENTAL): 4 milligrams (mg) perampanel tablet
- Treatment B (Type: EXPERIMENTAL): 4 mg perampanel fine granules

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Long-term, High-dose N-acetylcysteine on Exacerbations of Bronchiectaisis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. subjects were aged 18-80 years old;~2. a diagnosis of idiopathic or post-infective bronchiectasis was made;~3. patients had at least two exacerbations in the past year and were in a stable state for at least 4 weeks prior to the primary enrollment.~Exclusion Criteria:~Patients were excluded if they fulfilled any of the following criteria: current smokers; cigarette smoking within 6 months; cystic fibrosis or other etiologies (such as immunodeficiency, allergic bronchopulmonary aspergillosis, traction bronchiectasis caused by emphysema, advanced pulmonary fibrosis, etc.); pulmonary function test results showing a forced expiratory volume in 1 s (FEV1) ≤ 30% of the predicted value; a history of severe cardiovascular or neurological disease; comorbidity with liver disease, kidney disease, malignant tumor, gastric ulcer, or intestinal malabsorption; a known allergy to N-acetylcysteine; pregnancy or lactation (for women); a history of prior macrolide use of more than 1 week; and poor compliance.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- N-Acetylcysteine group (Type: ACTIVE_COMPARATOR): Participants received 600 mg of oral N-acetylcysteine BID for 12 months.
- Control group (Type: OTHER): Participants received as-needed therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Main Inclusion Criteria:~* Patients with unresectable stage III or stage IV cutaneous melanoma, as per American Joint Committee on Cancer (AJCC) (Version 8) staging system (must have been histologically confirmed at least once during course of disease). Patients with metastatic tumor of unknown primary site and histology of melanoma are eligible.~* Patients must be primary refractory or non-responding to anti-PD-1 therapy (either as monotherapy or in combination with Ipilimumab)~* Measurable disease by computer tomography (CT) or Magnetic resonance imaging (MRI) per immune-related response evaluation criteria in solid tumors (irRECIST) 1.1 criteria, with longest diameter for non-nodal lesions ≥ 10 mm and ≥ 15 mm in short axis for nodal lesions~* At least one tumor site (either primary site or metastasis) must be accessible for sequential biopsies and patient must consent to the 2 mandatory biopsies. This requirement is not applicable for continuous dosing schedules and may be waived by the sponsor in other individual cases.~Main Exclusion Criteria:~* Patients who achieved a CR or PR, during or after prior anti-PD-1 mono- or anti-CTLA-4/anti-PD-1 combination therapy~* Patients with symptomatic brain metastases/central nervous system (CNS) involvement~* Patients with inadequate organ function~* Therapy with agents known to prolong the QT interval and increase the risk for Torsades de Pointes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 4SC-202 + Pembrolizumab (Type: EXPERIMENTAL): Single arm study of 4SC-202 in combination with Pembrolizumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-70 yrs, male and females, with T2DM, on metformin alone or in combination with 1 other oral agent~Exclusion Criteria:~* Subjects with recent cardiovascular events, those with evidence of diabetic complications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to match PF-04937319 and glimepiride
- PF-04937319 10 mg (Type: EXPERIMENTAL): None
- PF-04937319 50 mg (Type: EXPERIMENTAL): None
- PF-04937319 100 mg (Type: EXPERIMENTAL): None
- Glimepiride (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Simvastatin on Th17 Cytokines and Th17 Polarizing Cytokine in COPD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stable COPD without an exacerbation within 3 months prior to study entry~* mild, moderate and severe COPD with or without treatments, regardless of COPD medications~Exclusion Criteria:~* Concomitant other chronic lung diseases including with TB and malignancy~* HIV~* Being on immunosuppressive drugs and systemic corticosteroids~* Dyslipidemic patients with recent cardiovascular or cerebrovascular disease within 6 month prior to study entry~* Cognitive impairment~* Currently on macrolides, azole anti-fungal agents, amiodarone and amlodipine

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Simvastatin (Type: EXPERIMENTAL): simvastatin 20 mg/d is randomized to treat COPD patients for 4 weeks
- B1-6-12 (Type: PLACEBO_COMPARATOR): B1-6-12 one tablet a day is randomized to give to COPD patients for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ambulatory women with post-menopausal osteoporosis;~* patients who are bisphosphonate-naive, or who have previously received oral daily or i.v. bisphosphonate therapy (fulfilling certain criteria detailed in the protocol).~Exclusion Criteria:~* malignant disease diagnosed within previous 10 years (except for successfully resected basal cell cancer;) breast cancer within previous 20 years;~* inability to stand or sit upright for at least 60 minutes;~* disease/disorder/treatment with drugs known to influence bone metabolism.

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Electronic Informed Consent Information (EICI) on Residual Newborn Specimen Research

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~* adult (\> 18 years)~* English-speaking~* Recently given birth and are already being approached for participation in the Michigan BioTrust.~* Partner of woman who has recently given birth and is already being approached for participation in the Michigan BioTrust~Exclusion criteria~* Newborn baby is in the NICU~* Unable to speak English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Intervention (Type: ACTIVE_COMPARATOR): The EICI intervention group will receive an electronic interactive tool with movie clips and external links available through the tool. The movie intervention group will watch the educational consent movie and receive the standard paper-based brochure.
- Control (Type: PLACEBO_COMPARATOR): This group will receive the standard of care currently used (paper-based brochure)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Aging Endocrine Pancreas: Characterization of the Entero-insular Axis Physiology in the Elderly

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Stable weight (\< 5% variation) within the last three months~* Age: 35 to 50 years old for middle-age group, and 65 to 80 years old for elderly group.~* BMI: 20 to 29.9 kg/m2~* Normal glucose tolerance (NGT) for groups Elderly and Middle-age~Exclusion Criteria:~* Use of estrogen, progestogen or systemic corticosteroids.~* Hepatic cirrhosis, renal failure or any clinical condition with impaired insulin sensitivity~* Smoking~* Obesity~* Uncontrolled systemic or debilitating diseases

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Elderly NGT (Type: None): Normoglycemic subjects 65-80 years old
- Middle-age NGT (Type: None): Middle-age normoglycemic subjects 35 to 50 years old.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Topical Cyclosporine for Atopic Keratoconjunctivitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has known diagnosis of atopic keratoconjunctivitis~* Patient has been on cyclosporine 0.05% eye drops for control of atopic keratoconjunctivitis~* Patient has been followed up for at least for 1 year~* Patient is able to give informed consent~* Patient is able to tolerate a full ophthalmic exam~Exclusion Criteria:~* Patient has any other diagnosis (i.c. vernal keratoconjunctivitis, giant papillary conjunctivitis) that may alter the clinical appearance or behavior of their ocular surface)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cyclosporine 0.05% ophthalmic (Type: EXPERIMENTAL): cyclosporine 0.05% ophthalmic eye drops will be used starting with 1 drop in both eyes 6 times daily for first month, followed by 1 drop in both eyes 4 times daily for the following month, then will be adjusted by clinician as needed for appropriate disease control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Transitioning From Alendronate to Denosumab

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal females 55 yrs or older~* Received alendronate therapy for osteoporosis for at least 6 months prior to entry into study~* Lumbar spine or total hip Bone Mineral Density (BMD) corresponding to T-score ≤ -2 and ≥ -4~Exclusion Criteria:~* Vitamin D deficiency~* Administration of intravenous bisphosphonate, or~* fluoride (except for dental treatment) or~* strontium ranelate~* Administration of Parathyroid Hormone (PTH) or Parathyroid Hormone (PTH) derivatives (eg; teriparatide) within the last year~* Administration of any bisphosphonate other than alendronate (ALN) within 1 year of screening

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- denosumab (Type: EXPERIMENTAL): None
- alendronate (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with CDAD~Exclusion Criteria:~* Patients with severe CDAD

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete